James Carmichael

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

J. Carmichael, J. Dixon, J. Jaśkiewicz, 2013, Investigational New Drugs.